TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Typical form | Lyophilised powder | Reconstituted before use |
| Storage temperature, dry | -20 °C or below | Desiccated, protected from light |
| Purity determination | Reversed-phase HPLC | Reported as percentage of total peak area |
| Identity confirmation | Mass spectrometry | ESI or MALDI-TOF versus calculated mass |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies between suppliers |
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
== Policy and advocacy == As the pre-eminent body representing human genetics in Oceania, the HGSA authors numerous policies and position statements to guide practitioners in the region. Such documents cover diverse topics such as genomic testing; screening for genetic disorders; ethical practice in genomics; genetic education; and clinical service delivery. In addition, the HGSA actively comments on policy and guidelines authored by other institutions and provides expert advice to government and genomic regulatory authorities.
This causes a slow accumulation of mutations and results in the development of cancers. An example of such a hereditary cancer syndrome is xeroderma pigmentosum, which causes the development of skin cancers in response to even minimal exposure to ultraviolet light.
=== Intralesional injections === Intralesional injection therapy is part of non-surgical therapy, particularly for stable disease. Verapamil and interferon alfa-2b have intermediate efficacy. Collagenase Clostridium histolyticum (CCH), an enzymatic drug approved by the US Food and Drug Administration (FDA), targets plaque collagen and repairs in moderate disease. It is administered in a series of treatment cycles with attendant penile modeling and elongation. Potential side effects include corporal rupture (penile fracture) or other serious penile injury.
== Prevention by food == Scurvy can be prevented by a diet that includes uncooked vitamin C-rich foods providing as little as 10 mg of vitamin C per day. Common examples in typical serving amounts include kiwifruit, grapefruit, strawberries, bell peppers, and citrus fruits. About five servings per day of fresh fruits and vegetables supply enough vitamin C to exceed the scurvy threshold by 10-fold. Nutritional supplements that provide ascorbic acid well above what is required to prevent scurvy may cause adverse health effects. Uncooked fresh meat from animals, notably internal organs such as liver, contains enough vitamin C to prevent scurvy, and even partly treat it. Scott's 1902 Antarctic expedition used fresh seal meat and increased allowance of bottled fruits which reportedly led to complete recovery from incipient scurvy in less than two weeks.
Classical EDS is characterized by extremely elastic skin that is fragile and bruises easily, and hypermobility of the joints. Molluscoid pseudotumors (calcified hematomas that occur over pressure points) and spheroids (cysts that contain fat occurring over forearms and shins) are also often seen. A side complication of the hyperelasticity presented in many EDS cases makes wound closure on its own more difficult. Sometimes, motor development is delayed and hypotonia occurs. The variation causing this type of EDS is in the genes COL5A2, COL5A1, and less frequently COL1A1. It involves the skin more than hEDS. In classical EDS, large variation in symptom presentation is seen. Because of this variance, EDS has often been underdiagnosed. Without genetic testing, healthcare professionals may be able to provide a provisional diagnosis based on careful examination of the mouth, skin, and bones, as well as by neurological assessment. A good way to begin the diagnostic process is by reviewing a person's family history. EDS is an autosomal dominant condition, so it is often inherited from parents. Genetic testing remains the most reliable way to diagnose EDS. No cure for type 1 EDS has been found, but a course of non-weight-bearing exercise can help with muscular tension, which can help correct some EDS symptoms. Anti-inflammatory drugs and lifestyle changes can help with joint pain. Lifestyle choices should also be made with children who have EDS to try to prevent wounds to the skin. Protective garments can help with this.
Sources: en.wikipedia.org
Furious about being woken early, Viktor refuses to believe Selene's warnings about Kraven's treachery and reminds her that his fellow elder Marcus was supposed to be awakened before him. Meanwhile, en route to the mansion to awaken Marcus, vampire elder Amelia, the coven's current ruler, is ambushed and killed by Lycans, who have tracked her with Kraven's assistance. Selene escapes the mansion and abducts the Lycan scientist Singe, while the Lycans capture Michael. While held captive in the Lycans' lair, Michael soon learns that Lucian was once in love with Viktor's daughter Sonja. After he discovered their forbidden affair, Viktor murdered her. Lucian claims that Lycans were once slaves of vampires, and the war began when they rose up against them and fought for their freedom. At the vampires' mansion, a captive Singe reveals that Selene was being honest about Kraven's betrayal, and he reveals why the Lycans want Michael: vampires and Lycans actually have a common ancestor, which Michael is a direct descendant of. As an heir to the legendary "Corvinus" bloodline, he carries a unique genetic strain that could allow him to become a vampire-werewolf hybrid, which Singe predicts will lack the weaknesses of both species. An angered Viktor then kills Singe and mobilizes the Death Dealers to raid the Lycan’s lair to kill the remaining Lycans, including Michael. In the ensuing showdown between vampires and Lycans, Selene breaks into the Lycans' lair to rescue Michael.
Deka Bike (デカバイク, Deka Baiku): Deka Break's personal police motorcycle-themed Deka Machine that can be ridden by Dekaranger Robo in the Riding Dekaranger Robo (ライディングデカレンジャーロボ, Raidingu Dekarenjā Robo) formation, allowing it to perform the Riding Justice Flasher (ライディングジャスティスフラッシャー, Raidingu Jasutisu Furasshā) attack. Blast Buggy (ブラストバギー, Burasuto Bagī): A combat vehicle–themed Deka Machine from S.P.D.'s Planet Leslie branch that Deka Break pilots during the events of the film Tokusou Sentai Dekaranger The Movie: Full Blast Action.
=== Controversy === In 2010, Novo Nordisk breached the Association of the British Pharmaceutical Industry's code of conduct by failing to provide information about side effects, and by promoting it prior to being granted market authorization. In 2012, the non-profit consumer advocacy group Public Citizen petitioned the US Food and Drug Administration (FDA) to immediately remove liraglutide from the market because they concluded that risks of thyroid cancer and pancreatitis outweigh any documented benefits. In 2017, Novo Nordisk agreed to pay $58.65 million to settle multiple whistleblower lawsuits alleging that the company had illegally marketed, promoted, and sold Victoza for off-label uses (such as for type 1 diabetes) in violation of the Federal Food, Drug, and Cosmetic Act and the False Claims Act. Novo Nordisk paid an additional $1.45 million to the states of California and Illinois to settle whistleblower cases alleging fraud against private commercial health insurers.
=== Category:EC 1.8 (act on a sulfur group of donors) === Category:EC 1.8.1 (with NAD+ or NADP+ as acceptor) Glutathione reductase EC 1.8.1.7 Thioredoxin reductase EC 1.8.1.9 Category:EC 1.8.2 (with a cytochrome as acceptor) Category:EC 1.8.3 (with oxygen as acceptor) Sulfite oxidase EC 1.8.3.1 Category:EC 1.8.4 (with a disulfide as acceptor) Category:EC 1.8.5 (with a quinone or similar compound as acceptor) Category:EC 1.8.6 deleted, included in EC 2.5.1.18 Category:EC 1.8.7 (with an iron–sulfur protein as acceptor) Category:EC 1.8.98 (with other, known, acceptors) Category:EC 1.8.99 (with other acceptors)
Sources: en.wikipedia.org
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.
Synthesis routes, purification steps and the analytical method used all affect the reported figure. A purity number is only comparable when the chromatographic conditions and detection wavelength are stated.
It reports what the supplier measured on a sample, which is useful but not absolute. Independent mass confirmation on the received lot is the more reliable check.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.